PPAR Agonists
Cross-source consensus on PPAR Agonists from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Highlighted claims
- PPARα primarily drives fatty acid β-oxidation in hepatocytes, reducing hepatic fat accumulation. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- PPARα exerts anti-inflammatory effects through transrepression of NF-κB-driven cytokine and chemokine production. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- PPARβ/δ enhances glucose utilisation, regulates de novo lipogenesis, and activates Kupffer cells to contribute to hepatic insulin sensitivity. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- PPARγ maintains hepatic stellate cells in a quiescent state, thereby preventing hepatic fibrogenesis. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- PPARγ facilitates redistribution of adipose tissue from the liver to subcutaneous depots during adipocyte differentiation. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol
- PPARγ alleviates endoplasmic reticulum stress by inducing Nogo-B receptor expression and reducing PERK and IRE1 signalling. — Chiglitazar in combination with anti-inflammatory and hepatoprotective therapy for the treatment of MASH associated with T2DM: a prospective, multicentre, randomised, double-blind, placebo-controlled study protocol